Cargando…
Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports
BACKGROUND: Many scientists across the world got involved in the race to develop successful anti-SARS-CoV-2 vaccines to overcome COVID-19 pandemic. Among the different vaccines developed against SARS-CoV-2, Covishield was the first vaccine approved for emergency use in Nepal. We report two cases of...
Autores principales: | Sah, Mukesh Kumar, Singh, Bishnu Mohan, Sinha, Puja, Devkota, Prerit, Yadav, Sudhira Kumari, Shrestha, John, Shrestha, Ashis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076162/ https://www.ncbi.nlm.nih.gov/pubmed/35524323 http://dx.doi.org/10.1186/s13256-022-03407-6 |
Ejemplares similares
-
Correction: Superficial venous thrombosis as a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports
por: Sah, Mukesh Kumar, et al.
Publicado: (2022) -
Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021) -
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022) -
Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022) -
Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)